Thomas Fuller | Lightrocket | Getty ImagesReplimune plans to resubmit its melanoma drug to the Food and Drug Administration for review after a leadership exodus at…

IO Biotech to announce Phase 3 melanoma treatment results Read More: IO Biotech to announce Phase 3 melanoma treatment results By Investing.com